Idm Pharma Inc

Idm Pharma — Epimmune — Merger or Acquisition (April 2005)

27 slides from Idm Pharma's merger presentation, Apr 22, 2005

  1. Slide 1: Epimmune and IDM Business Combination April 2005

    Epimmune and IDM Business Combination April 2005

  2. Slide 2: Safe Harbor Statement

    This presentation includes forward-looking statements that reflect management's current views of future events such as statements about the projected benefits of the combination with IDM, our contributions to the combined company and the pro forma financial statements for the proposed combined compa

  3. Slide 3: Key elements of an effective vaccine

    "Key elements of an effective vaccine include: the antigen, against which adaptive immune responses are elicited; immune potentiators to stimulate the innate immune system; and delivery systems to ensure that the vaccine is delivered to the right place at the right time." Jeffrey B. Ulmer, Nature Me

  4. Slide 4: Epimmune-IDM Combination: antigens, potentiators, delivery systems

    1. Epimmune contributes the antigens 2. Epimmune and IDM join their immune potentiators 3. IDM contributes the delivery systems Epimmune-IDM Combination

  5. Slide 5: Mission: empower the patient's immune system

    Mission: To empower the patient's immune system to fight against cancer and chronic viral infections. Epimmune-IDM Combination

  6. Slide 6: Combination: The Terms

    Epimmune Inc. combines with IDM S.A. 1 IDM share to be exchanged for 3.77 Epimmune shares The combined company will have 102 million shares outstanding*, 22% Epimmune and 78% IDM Pro-forma combined cash balance of approximately $41M after deducting transaction expenses * Before any contemplated reve

  7. Slide 7: Combination: The Rationale

    Starting point: July 2003 license deal Natural next step following a long standing relationship Stronger product pipeline: one drug candidate, Mepact, has completed Phase III six other candidates in clinical development Increasing capabilities in immunotherapy R&D Achieving critical mass Diversifyin

  8. Slide 8: Combination: Company Backgrounds

    IDM 1993 founded in Paris Located in Irvine, CA and Paris, France 115 employees Private VC-backed Combination expected to close in Q3 2005 Epimmune 1997 spin-out from Cytel and subsequent reorganization to focus on epitope-based vaccine technology Located in San Diego, CA 40 employees Public co. (Na

  9. Slide 9: What IDM Brings to the Combination

    Mepact Phase III trial completed Mepact revenues expected in 2007 Sanofi-Aventis product partnership Three additional products in clinical trials Dendritic cell, macrophage and liposome technology Top venture and strategic investors; 100M € invested Atlas, Apax, Alta Partners, Sofinnova Sanofi-Avent

  10. Slide 10: What Epimmune Brings to the Combination

    Phase II trial in non-small cell lung cancer Infectious disease pipeline: Phase I/II HIV, Phase I HBV Strong NIH support and sponsorship Unique technology to break immune tolerance with modified epitopes Innogenetics partnership (HBV, HCV, HPV) Existing annual revenue flow of $7M to $9.5M ('01 to '0

  11. Slide 11: Combined Company Highlights

    Focused in cancer and chronic infectious diseases Epitopes + dendritic cell delivery to address therapeutic vaccines Stronger product pipeline: 7 clinical / 6 preclinical Mepact revenues expected in 2007 Key strategic partnerships with Sanofi-Aventis and Innogenetics 18-24 months of cash as of 1/1/0

  12. Slide 12: Synergistic Technologies

    COLLIDEM IDD-6 ELADEM-2 BREAST LUNG Epitopes + Dendritic Cells = More Product Opportunities (EPMN) (IDM) Synergistic Technologies

  13. Slide 13: Stronger Product Pipeline

    Stronger Product Pipeline Ph III trial completed MEPACT Osteosarcoma IDM Candidate Indication Phase I Phase II Phase III Marketing Rights EP-2101 NSCLC Ph II EPMN EP-HIV-1090 Ph I/II AIDS EP-HBV Hepatitis B Ph I Ph II/III BEXIDEM Bladder cancer IDM Ph II UVIDEM Melanoma COLLIDEM Colorectal cancer ID

  14. Slide 14: Mepact: Product Definition

    Liposomal formulation of Muramyl Tri Peptide Phosphatidyl Ethanolamine (MTPE) Activates macrophages, cytokines in vivo Development started by Ciba-Geigy (now Novartis) Mepact: Product Definition

  15. Slide 15: Mepact Indication: Osteosarcoma

    Bone cancer Age of 10-25 High-grade Intermediate Surgery and chemotherapy Low-grade U.S. incidence = 900 cases per year EU incidence = 900 cases per year Pulmonary metastases are the challenge Mepact Indication: Osteosarcoma

  16. Slide 16: Mepact: Phase III Design

    + Mepact + Mepact Mepact: Phase III Design

  17. Slide 17: Mepact: Phase III Disease-Free Survival Results

    Variable # of Pts (# relapse or death) P-value Hazard Ratio 95% CI for HR NO Mepact 332 (123) - 1.00 - + Mepact 332 (99) 0.030 0.75 0.58-0.98 The addition of Mepact to chemotherapy significantly improves DFS Mepact: Phase III Disease-Free Survival (DFS) Results

  18. Slide 18: Mepact: Phase III Overall Survival Results

    Variable # of Pts (# Deaths) P-value Hazard Ratio 95% CI for HR NO Mepact 332 (80) - 1.00 - + Mepact 332 (61) 0.039 0.70 0.50-0.98 The improvement in disease-free and overall survival in eligible patients with non-metastatic, resectable disease who were randomized to Mepact corresponds to a relative

  19. Slide 19: Mepact: Expected to Reach Market in 2007

    Exclusive worldwide sales and marketing rights Orphan drug designation in the U.S. and in Europe Launch anticipated in 2007 Annual worldwide market potential ~$100 million Company focused sales force in the U.S. and Continental Europe Manufacturing outsourced Mepact: Expected to Reach Market in 2007

  20. Slide 20: Sanofi-Aventis-Supported Phase II: Uvidem

    Cell Drug: dendritic cells loaded with melanoma cell lysates Targeting melanoma - the most deadly form of skin cancer Addresses unmet medical need Phase I/II trial completed 14 Stage IV melanoma patients Well-tolerated product with no major associated toxicity Preliminary indications of effectivenes

  21. Slide 21: Our Phase II Clinical Trials

    EP-2101: Stage IIIB, IV or recurrent disease NSCLC patients A2+, good performance status, low tumor burden Open-label study; compare to historical controls and an observation group Same treatment as in Phase I, single dose level Primary endpoint: safety and overall survival Secondary endpoint: progr

  22. Slide 22: Our Phase I/II Clinical Trials

    Collidem: Cell drug: dendritic cells loaded with peptides Targeting colorectal cancer - the third most common cause of death from cancer in the U.S. Phase I/II clinical trial in the U.S. to evaluate immune and clinical responses in addition to safety in patients with metastatic colorectal cancer San

  23. Slide 23: Combined Company: Key Relationships

    Combined Company: Key Relationships

  24. Slide 24: Combined Company: Financials (unaudited)

    Combined Company: Financials (unaudited) Pro Forma Condensed Combined Year Ended December 31, 2004 Statements of Operations Data (in thousands, except per share data) Total revenues $ 15,218 Loss from operations (53,195 ) Net loss (52,068 ) Basic and diluted net loss per share (0.57 ) Shares used in

  25. Slide 25: Combined Company: Key People

    Combined Company: Key People Jean-Loup Romet-Lemonne, M.D. Chairman, Chief Executive Officer Emile Loria, M.D. President, Chief Business Officer Robert De Vaere Vice President, CFO Guy-Charles de la Horie, D.V.M., M.B.A. Vice Pres., Gen'l Manager, France Bonnie Mills, Ph.D. Vice Pres., Gen'l Manager

  26. Slide 26: Expected 18-Month Milestones

    Mepact Phase III data at ASPHO Melanoma cancer vaccine Phase I/II data at ASCO Complete combination (Q3) Mepact distribution agreement for UK Start Bexidem Phase II/III trial in bladder cancer in the U.S. Special Protocol Assessment for Bexidem Phase II/III Complete EP-2101 Phase II trial recruitmen

  27. Slide 27: Epimmune and IDM Business Combination April 2005

    Epimmune and IDM Business Combination April 2005

Epimmune — Merger or Acquisition (April 2005) on 6ix